CompletedPhase 2

Bone Mass and Strength After Kidney Transplantation

United States61 participantsStarted 2014-08-18

Plain-language summary

The purpose of this study is to test whether active vitamin D (calcitriol) protects bones from weakening and protects blood vessels from calcium deposits over the first year of kidney transplantation.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age older than 18 * Self-describes as White race Exclusion Criteria: * Lower extremity amputations * Non-ambulatory * Paget´s disease of bone * Current hyperthyroidism, untreated hypothyroidism * Medical diseases (end stage liver, intestinal malabsorption) * Use within the prior year pod anti-seizure medications that induce the cytochrome P450 system, testosterone, estrogen, selective estrogen receptor modulators * Weight \>300 pounds * Dual organ transplant * Myocardial infarction or stroke * Tobacco use within the past year

What they're measuring

Percent Change in Bone Density From Pre to Post-calcitriol Treatment Compared to Placebo as Assessed by Both Standard Methodologies

Timeframe: Baseline, 12 months

Trial details

NCT IDNCT02224144

SponsorColumbia University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-10-12

Results submitted2025-02-10

View on ClinicalTrials.gov More End Stage Renal Disease trials